D. E. Shaw & Co. Inc. Buys Shares of 11,691 Affimed NV (AFMD)
D. E. Shaw & Co. Inc. bought a new position in Affimed NV (NASDAQ:AFMD) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 11,691 shares of the biopharmaceutical company’s stock, valued at approximately $36,000.
A number of other institutional investors have also recently modified their holdings of AFMD. FMR LLC bought a new position in Affimed in the 3rd quarter worth $5,552,000. Stonepine Capital Management LLC bought a new position in shares of Affimed during the 4th quarter valued at about $2,221,000. Telemetry Investments L.L.C. boosted its holdings in shares of Affimed by 127.9% during the 4th quarter. Telemetry Investments L.L.C. now owns 425,398 shares of the biopharmaceutical company’s stock valued at $1,323,000 after purchasing an additional 238,719 shares during the last quarter. Bellevue Group AG bought a new position in shares of Affimed during the 4th quarter valued at about $529,000. Finally, Keybank National Association OH bought a new position in shares of Affimed during the 4th quarter valued at about $218,000. 41.06% of the stock is owned by institutional investors.
Several research analysts have commented on the stock. Zacks Investment Research raised shares of Affimed from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Friday, April 12th. ValuEngine downgraded shares of Affimed from a “buy” rating to a “hold” rating in a report on Friday, March 29th. Svb Leerink assumed coverage on shares of Affimed in a report on Thursday, March 28th. They set an “outperform” rating and a $8.00 price objective for the company. Finally, Leerink Swann assumed coverage on shares of Affimed in a report on Thursday, March 28th. They set an “outperform” rating and a $4.17 price objective for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Affimed has an average rating of “Buy” and an average target price of $5.15.
Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. Affimed had a negative net margin of 87.00% and a negative return on equity of 44.56%. The business had revenue of $25.96 million during the quarter. On average, sell-side analysts forecast that Affimed NV will post -0.48 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2019/04/20/d-e-shaw-co-inc-buys-shares-of-11691-affimed-nv-afmd.html.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: What is net income?
Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed NV (NASDAQ:AFMD).
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.